OPEN ACCESS Freely available online

Journal of Clinical Trials

Opinion Article

The Role of Transparency in Discontinued Clinical Trials and Ethical Imperatives and Practical Benefits

Shanshan Zhao*

Department of Medicine, Stanford University School of Medicine, California, USA

DESCRIPTION

Clinical trials are fundamental to the advancement of medical science and the development of new treatments. However, not all trials reach completion; some are discontinued due to various reasons, ranging from safety concerns to insufficient efficacy. Ensuring transparency in these discontinued clinical trials is important for several ethical and practical reasons. Transparency in discontinued clinical trials plays a key role in shaping clinical practice guidelines [1]. When data from these trials are openly shared, it allows healthcare professionals to make informed decisions, ultimately improving patient care. It also helps in identifying potential risks or shortcomings that might not have been apparent in pre-clinical trials. The intersection of clinical research and bioethics underscores the ethical imperatives of transparency. Patients who participate in clinical trials do so with the understanding that their involvement will contribute to scientific knowledge.

Importance of transparency in clinical trials

Clinical trials play an important role in the advancement of medical science and the development of new treatments. Transparency in these trials, especially when they are discontinued, is vital for several reasons [2]. First and foremost, upholding ethical standards in clinical research and bioethics demands clear communication about why a trial has been stopped. This openness ensures that participants, researchers and the public understand the safety and efficacy issues that led to the discontinuation. Transparency in discontinued clinical trials also holds practical benefits. When trial data is openly shared, it can inform future research efforts and prevent the repetition of past mistakes. For instance, understanding the reasons behind a trial's discontinuation can help refine clinical practice guidelines and improve the design of future research studies [3]. This sharing of information encourages a more collaborative and efficient scientific community, ultimately accelerating the path to medical innovations. Moreover, the ethical imperatives of transparency cannot be overstated. Participants who volunteer for clinical trials do so with the hope of contributing to medical advancements. When a trial is discontinued, they deserve to know the reasons behind it. This respect for their contribution upholds the principles of clinical research and bioethics, reinforcing public trust in the research process. In addition, transparency in pre-clinical trials is equally important [4]. Early-stage research often sets the foundation for later clinical trials, and sharing data on discontinued pre-clinical studies can prevent unnecessary duplication of efforts. It also helps in refining research hypotheses and methodologies, thereby contributing to more robust and successful clinical trials in the future.

Ethical imperatives in discontinued clinical trials

Clinical trials are fundamental to advancing medical knowledge and improving patient care. However, when a clinical trial is discontinued, it becomes important to address ethical imperatives that ensure transparency and protect the interests of all associates, including patients, researchers and the broader medical community [5].

Transparency in reporting

Ensuring transparency in the reporting of discontinued clinical trials is vital. Researchers have an ethical obligation to provide a clear rationale for halting the study, whether due to safety concerns, efficacy issues, or other logistical challenges. This information should be openly shared in clinical practice guidelines to inform future research and clinical decisions [6].

Protecting participant welfare

Ethical imperatives in discontinued clinical trials also emphasize the protection of participant welfare. Clear communication with participants about the reasons for discontinuation, potential risks and follow-up care is important. This aligns with broader principles of clinical research and bioethics, ensuring that participants are not left in uncertainty or at unnecessary risk [7,8].

Correspondence to: Shanshan Zhao, Department of Medicine, Stanford University School of Medicine, California, USA, E-mail: Shanshan@zhao.edu

Received: 30-Jul-2024, Manuscript No. JCTR-24-33933; **Editor assigned:** 01-Aug-2024, PreQC No. JCTR-24-33933 (PQ); **Reviewed:** 15-Aug-2024, QC No. JCTR-24-33933; **Revised:** 22-Aug-2024, Manuscript No. JCTR-24-33933 (R); **Published:** 30-Aug-2024, DOI: 10.35248/2167-0870.24.S29.001

Citation: Zhao S (2024). The Role of Transparency in Discontinued Clinical Trials and Ethical Imperatives and Practical Benefits. J Clin Trials. S29:001.

Data sharing and future research

Transparency extends to the sharing of data from discontinued trials. Even if a trial does not reach its intended conclusion, the data collected can provide valuable insights. Sharing this data responsibly can guide future research directions, improve clinical practice guidelines and enhance the ethical framework within clinical research and bioethics [9,10].

Regulatory compliance

Adhering to regulatory requirements is another essential aspect. Discontinued clinical trials must comply with reporting standards set by regulatory bodies. This ensures that pre-clinical trials and other related research phases maintain a consistent ethical standard, promoting trust and integrity in the scientific community.

CONCLUSION

In conclusion, clinical trials demand a high level of ethical responsibility, particularly when they are discontinued. By prioritizing transparency, protecting participant welfare, sharing data and adhering to regulatory standards, the medical community can uphold the integrity of clinical research and bioethics, ultimately leading to more reliable and ethical medical advancements.

REFERENCES

1. Dolwick MF, Widmer CG. Orthognathic surgery as a treatment for temporomandibular disorders. Oral and Maxillofac Surg Clin North Am. 2018;30(3):303-323.
2. Hunt OT, Johnston CD, Hepper PG, Burden DJ. The psychosocial impact of orthognathic surgery: A systematic review. Am J Orthod Dentofacial Orthop. 2001;120(5):490-496.
3. Ferri J, Druelle C, Schlund M, Bricout N, Nicot R. Complications in orthognathic surgery: A retrospective study of 5025 cases. Int Orthod. 2019;17(4):789-798.
4. Guo J, Gao X, Ma Y, Lv H, Hu W, Zhang S, et al. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: A meta-analysis of randomized trials. BMC Anesthesiol. 2019;19(1):1-6.
5. Amer KM, Rehman S, Amer K, Haydel C. Efficacy and safety of tranexamic acid in orthopaedic fracture surgery: A meta-analysis and systematic literature review. J Orthop Trauma. 2017;31(10): 520-525.
6. McCormack PL. Tranexamic acid: A review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72(5):585-617.
7. Rummasak D, Apipan B, Kaewpradup P. Factors that determine intraoperative blood loss in bimaxillary osteotomies and the need for preoperative blood preparation. J Oral Maxillofac Surg. 2011;69(11):e456-460.
8. Robertson J, Koyfman A. Does tranexamic acid improve outcomes in patients undergoing urgent or emergency surgery? Ann Emerg Med. 2015;65(4):445-446.
9. Apipan B, Rummasak D, Narainthonsaenee T. The effect of different dosage regimens of tranexamic acid on blood loss in bimaxillary osteotomy: A randomized, double-blind, placebo-controlled study. Int J Oral Maxillofac Surg. 2018;47(5):608-612.
10. Chegini S, Dhariwal DK. Review of evidence for the use of steroids in orthognathic surgery. Br J Oral Maxillofac Surg. 2012;50(2):97-101.